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INTRODUCTION
Introduction of genes encoding proteins of potential ther-
apeutic value into the central nervous system (CNS) may be
the most effective method for treating CNS disorders such as
brain cancer, Huntington disease, and Alzheimer disease. To
achieve this goal, effective transfer and stable expression of
the transgenes in the CNS are essential. To date, several dif-
ferent delivery methods have been demonstrated using pro-
tein/DNA complex, mechanical administration, liposomes,
and recombinant viral vectors (1). Introduction of foreign genes
in terminally differentiated cells like CNS neurons has been
practically a highly challenging task, but the field of gene ther-
apy of the CNS has been greatly expanded due to the avail-
ability of several recombinant viral vectors. Such viral vectors
include adeno-associated virus (2-4). Herpes simplex virus (5,
6), vaccinia virus (7), and retrovirus (1, 8, 9), and all of these
vectors have successfully modified gene function in the CNS.
Among these viral vectors, adenoviral vectors have been exten-
sively used for the delivery of genes in the CNS. Several meth-
ods of delivering the viral vectors have been utilized, while
vascular delivery being the most recently introduced (10, 11).
This is different from other methods, and can optimize delivery
to the CNS without multiple invasive procedures.
The main aim of the present study was to characterize re-
porter gene expression in the CNS after intravenous injection
of adenoviral vectors containing green fluorescence protein
(GFP) genes, and thus provides a basis for developing gene
therapy of the CNS.
MATERIALS AND METHODS
Viral vector
The virus vector used in this study was a recombinant type
5 adenovirus vectors (Ad5) with disruption of the E1 and E3
regions, and contained the GFP gene placed under the control
of the cytomegalovirus (CMV) promoter. It was purchased
from Q-Biogene (Montreal, Canada). Viral stocks were generat-
ed in 293 cells, concentrated by ultracentrifugation, titered
by plaque assays (12), and stored in PBS containing 10% glyc-
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The delivery of transgenes to the central nervous system (CNS) can be a valuable
tool to treat CNS diseases. Various systems for the delivery to the CNS have
been developed; vascular delivery of viral vectors being most recent. Here, we
investigated gene transfer to the CNS by intravenous injection of recombinant
adenoviral vectors, containing green fluorescence protein (GFP) as a reporter gene.
Expression of GFP was first observed 6 days after the gene transfer, peaked at
14 days, and almost diminished after 28 days. The observed expression of GFP
in the CNS was highly localized to hippocampal CA regions of cerebral neocortex,
inferior colliculus of midbrain, and granular cell and Purkinje cell layers of cerebel-
lum. It is concluded that intravenous delivery of adenoviral vectors can be used for
gene delivery to the CNS, and hence the technique could be beneficial to gene
therapy.
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erol (v/v). 
Mice and adenoviral vector transfer
Each of the thirty adult, female BALB/c mice (8-12 weeks
old, 18-21 g; Charles-River Laboratory, Tokyo, Japan) were
injected with 0.3 mL of the virus stock (a total of 2×108 pfu)
via the tail vein. For the controls, only PBS containing 10%
glycerol (v/v) was injected. Five animals were sacrificed (by
cervical dislocation) at each point, 3, 6, 9, 14, 21 and 28 days
after intravenous injection. 
Immunohistochemical staining
The brains were extracted, fixed with 4% paraformaldehyde
in PBS (pH 7.4) and embedded in paraffin. For immunohisto-
chemical analysis, the brains were sectioned at 10 m in the
sagittal plane. Immunohistochemistry was performed follow-
ing the Vectastain ELITE protocol (Vector Laboratories, Bu-
lingame, U.S.A.) as previously reported (13). Anti-GFP anti-
body (Molecular Probes, Eugene, Oregon U.S.A.) was used
at a dilution of 1:3,000. Primary antibody was detected using
an avidin-biotin-peroxidase kit (Elite kit, Vectastain) and was
visualized with diaminobenzidine. Immunofluorescence also
was performed, as previously described (14), using rabbit anti-
GFP, mouse anti-NST (Neuron Specific Tubulin) (BabCo,
Richmond, CA, U.S.A.) and anti-GFAP (Santa Cruz Biotech.
Inc., Santa Cruz, CA, U.S.A.) antibodies. Anti-NST antibod-
ies recognized  -tubulin type III, that is specifically expressed
in neurons, whe-reas anti-GFAP antibodies recognized glial
filament associated proteins expressed exclusively in glial cells.
Secondary antibodies included FITC-conjugate (for GFP) and
rhodamine-conjugate (for NST and GFAP) (Jackson Immuno-
Research Laboratory, West Grove, PA, U.S.A.) and were used
at dilutions of 1:50 and 1:100, respectively.
RESULTS
GFP was expressed in the brain after intravenous injection
of the adenoviral vectors containing the GFP gene. Expression
was localized to the hippocampus of cerebral neocortex, infe-
rior colliculus of midbrain, and granular cell and Purkinje cell
layers of the cerebellum. In particular, CA regions of the hip-
pocampus showed robust expression of GFP (Fig. 1A), where-
as no expression was observed in dentate gyrus. GFP expres-
sion in the CA regions is highly localized to pyramidal cell
layers (Fig. 1A). Dendritic processes bearing GFP expression
were also observed. In the midbrain, GFP expression was found
in inferior colliculus, where it appeared in scattered cells. In
the cerebellum, GFP expression was highly localized to granu-
lar cell and Purkinje cell layers (Fig. 1B). Some GFP expression
was observed in molecular layers, representing possible projec-
tions of granular cells or Purkinje cells into these layers. The
expression of GFP in the brain changed with time after injec-
tion of viral vectors (Fig. 1B). GFP expression was first observ-
Fig. 1. GFP gene expression in the adult mouse brain. (A) Illustration of mid-line sagittal section of a mouse brain. Immunoreactivity of GFP
in hippocampal CA1-3 regions of cerebral neocortex is clearly visualized under 40×magnifications. The represented sample was acquired
14 days after injection. (B) Time course of GFP gene expression in the cerebellum. GFP is expressed in granular cell layer and Purkinje
cell layer of cerebellum. The expression of GFP was transient. The expression was peaked in 14 days after injection of viral vectors. Num-
ber of days indicated the day that the subjects were sacrificed after injection. Scale bars represent 100  m.
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ed from 6 days after injection and maintained intensely up to
14 days. Then, the expression was decreased and was barely
detectable after 28 days of injection. 
We also investigated if injected viral vectors could infect
either neurons and/or neuroglia and express GFP in these cells.
Neurons were immunohistochemically detected by anti-NST
antibodies (TuJ1), whereas neuroglia were identified by anti-
GFAP antibodies. The viral vectors used successfully infect-
ed both neurons and neuroglia, and GFP was expressed in
both cell types (Fig. 2). 
Expression of GFP in the heart, intestine, kidney, liver, lung,
and spleen were also examined. GFPs are well and most fre-
quently expressed on the lung among all examined organs.
GFP is highly expressed on the splenic trabecular area, renal
tubules and intestinal microvilli, but it is very sparsely express-
ed on the splenic pulp area, renal glomerulus, liver parenchy-
ma and heart. No specific pathologic lesions possibly related
with adenovirus administration are observed on microscopic
examination of all examined organs including the brain (15).
DISCUSSION
Our observations agree with the recent report from Smith
et al. (16) demonstrating a promoter dependent transfection
of the adenoviral vectors in vivo and in vitro. The adenoviral
vectors containing the CMV promoter were transfected into
CA regions and into pyramidal neurons of the rat hippocam-
pus, whereas minimal transfection was showed in the dentate
gyrus (16). In contrast, RSV promoter produced higher trans-
fection in the dentate gyrus and granular cells (16). Thus, selec-
tion of the promoter could be a critical consideration for the
design of adenoviral vectors for cell- or region-specific gene
delivery to brain. 
It may have been expected that the blood-brain barrier (B
BB), formed by the tight junctions of capillary endothelial cells
in the brain, would hinder the passage of most polar molecules,
including viral vectors (10). Consequently, to increase vector
delivery to brain by intracarotid artery infusion with osmotic
disruption of the BBB is used for the purpose of facilitating
transfection of viral vectors from blood to brain (17). Impor-
tantly, however, we demonstrated that the intravenously inject-
ed adenoviral vectors were able to enter the brain with an intact
BBB, although the adenoviral vectors used are much larger
than the open pore size of even disrupted BBB (10). It would
seem possible, therefore, that some unknown mechanism(s)
could enable the adenoviral vectors to cross the barrier. This
is an interesting phenomenon, and further studies may facil-
itate the development of more efficient delivery systems.
In this study, we demonstrated that intravenously injected
adenoviral vectors containing the CMV promoter are able to
cross the vascular epithelium in the brain, and infect neurons
or neuroglia without disruption of BBB. Thus, intravenous
delivery of recombinant adenoviral vectors is feasible for the
gene transfer to particular regions and cell types in the CNS.
Such an approach could, therefore, be a useful tool for gene
therapy of CNS disorders.
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